LOGIN
Denosumab reduces secondary fragility fracture risk in osteoporotic women
November 2015
Denosumab reduces secondary fragility fracture risk in osteoporotic women
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
Climacteric. 2015 Jun 1:1-23Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
7808 osteoperotic women part of the FREEDOM study, were analyzed in this post-hoc analysis. The purpose of this study was to determine how efficacious denosumab (60mg for 36 months) was in preventing fragility fractures and secondary fragility fractures as compared to a placebo. Results indicated that prior fragility fracture was present in 45% of the population, and denosumab treatment significan...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.